Fulcrum Therapeutics Reveals Topline Results from Phase 3 REACH Trial of Losmapimod in FSHD
Thursday, 12 September 2024, 03:55
Key Findings from the Losmapimod Trial
In the Phase 3 REACH trial, losmapimod did not achieve its primary outcome of relative surface area (RSA) improvement compared to placebo at week 48. This disappointing result suggests that current interventions may need re-evaluation.
Future Implications for FSHD Research
With the suspension of losmapimod's development by Fulcrum Therapeutics, researchers must pivot to explore alternative avenues in FSHD treatment.
- Need for Innovative Therapies
- Patient Support and Care
- Continued Advocacy for Muscle Disease Research
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.